Darren is CEO and Managing Director of Certa Therapeutic’s, bringing over 25 years of management and research expertise in the life sciences and biotech sector. Concurrent to his role with Certa Therapeutics, Darren is the CEO and MD of OccuRx, the Associate Dean (Innovation and Enterprise, MDHS) at The University of Melbourne, the Director of Innovation and Enterprise at the Centre for Eye Research Australia (CERA) and the Director Biomedical Research in the Department of Medicine, St Vincent’s Hospital Melbourne, where his research expertise lies in progressing preclinical novel interventions and developing experimental models of cardiovascular disease. He has published over 200 manuscripts in the field of translational research and novel interventions many of which have had a direct impact on human disease. In 2009, Darren was a recipient of the prestigious TJ Neale award for outstanding contribution to nephrology. In 2015 Darren joined the Medical Research Commercialisation Fund as VenturePartner.
Darren has proven history in translational research. He was previously Founder, CEO and Director of Fibrotech Therapeutics, a company that developed orally active anti‐fibrotic inhibitors to treat underlying pathological fibrosis in kidney and heart failure, which was ultimately acquired by Shire Plc for a record 75 million USD upfront including milestone payments up to 600 million USD.
Darren has a PhD in Translational Medicine from the University of Melbourne. He is a current member of the Australian Institute of Company Directors, AusBiotech, BioMelbourne Network and a Fellow of the American Society of Nephrology.
Details:
| Location: | Bio21 Institute, University of Melbourne |
| Start Date: | 22/08/2018 [add to calendar] |
| Start Time: | 4:00pm |
| End Date: | 22/08/2018 |
| End Time: | 6:00pm |
| RSVP By: | Friday 17th of August 2018 |
| Cost: | Free |
| Enquiries: | bridge.program@qut.edu.au |
| Register: |